Perspectives
Xeljanz® use for RA on the rise (but so is its discontinuation rate)
Nearly half of Xeljanz® users discontinue the costly RA drug after one year
February 9, 2017Prime research shows nearly half of Xeljanz® users discontinue the costly rheumatoid arthritis (RA) drug after one year
The FDA approved Tofacitinib (Xeljanz®) for people with RA who have an inadequate response to methotrexate. The study found that one in 10 members were potentially not following guidelines to use tofacitininb as second line therapy. Additionally, 44 percent of members discontinued the drug by one year. RA is a chronic condition that needs ongoing treatment; this study show there is opportunity for improvement. Plan sponsors should develop care and utilization management programs that encourage adherence and cost-effective treatment strategies.
Related news
Perspectives
July 25, 2024
Quarterly Drug Pipeline: July 2024
Clinical insights and competitive intelligence on anticipated drugs in development
Perspectives
July 22, 2024
Oncology Insights: 2024 ASCO Annual Meeting key findings
Findings from this year’s American Society of Clinical Oncology (ASCO) Annual Meeting will likely lead to clinical practice changes and U.S. Food and Drug Administration (FDA) drug approvals or expansions
Perspectives
July 16, 2024
LISTEN NOW: Beyond the business – Stories of corporate kindness | Pharmacy Friends Podcast
In this episode, we talk about how our employees' help goes beyond our work in health care, aiding in philanthropic efforts